Enliven Therapeutics Inc. (ELVN)
NASDAQ: ELVN
· Real-Time Price · USD
21.63
-0.66 (-2.96%)
At close: Jun 05, 2025, 1:40 PM
-2.96% (1D)
| Bid | 21.38 |
| Market Cap | 1.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -94.83M |
| EPS (ttm) | -1.92 |
| PE Ratio (ttm) | -11.27 |
| Forward PE | -7.81 |
| Analyst | Buy |
| Ask | 21.88 |
| Volume | 302,143 |
| Avg. Volume (20D) | 328,842 |
| Open | 22.00 |
| Previous Close | 22.29 |
| Day's Range | 21.43 - 22.60 |
| 52-Week Range | 13.30 - 30.03 |
| Beta | 0.95 |
About ELVN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ELVN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ELVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-10.41%
Enliven Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
8 months ago
+6.02%
Enliven Therapeutics shares are trading higher after the company provided more details regarding the presentation of its updated ELVN-001 Phase1a data of ESH-iCML at the 26th annual John Goldman Conference on CML.